Observational studies and some ophthalmology commentaries have been more reassuring overall, suggesting that many patients taking semaglutide do not experience clinically meaningful retinal worsening
The biggest external factor is regulatory: compounded GLP-1 availability is in transition under FDA enforcement, and anyone starting a program in June 2026 should understand what that means for supply continuity

Wegovy FDA highlights of prescribing information, Food and Drug Administration (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine (2021) Weight loss: UnitedHealthcare pharmacy clinical pharmacy programs, United Healthcare (2023) Pharmacy and prescription drug benefits, United Healthcare (2024) Prescription drug lists, United Healthcare (2024) Check your cost and coverage, Wegovy (2024) Find out if your insurance plan covers Wegovy, Novo Nordisk (2024) Wegovy savings offer and support program, NovoCare (2024) Ways to gain coverage for Wegovy, Wegovy (2024) Coverage request letter, Wegovy (2024) Real appeal, UnitedHealthcare (2023) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
[24] Lopresti AL, et al
14 mg SEMA tablets were sourced from Rybelsus